NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.705 +0.115 (+4.44%)

Delayed Quote Updated: 1:04 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NRX Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

What's Going On With NRX Pharmaceuticals Stock Thursday? ↗

January 02, 2025

NRX shares are trading higher on Thursday after the company announced a joint acquisition initiative with Hope Therapeutics to buy Kadima Neuropsychiatry Institute.

Via Benzinga

Why MicroStrategy Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗

January 02, 2025

Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply in today's pre-market trading.

Via Benzinga

New Drug Application to the FDA for the Treatment of Suicidal Depression that Affects Over 13 Million Americans Each Year: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)

December 31, 2024

Via Get News

Jonathan Javitt, CEO of NRx Pharmaceuticals Inc. (NASDAQ: NRXP), to Present at NobleCon20

November 13, 2024

Via Investor Brand Network

HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion ↗

August 26, 2024

HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP),

Via Benzinga

Plans for New Acquisition of Clinics Generating $100 Million to Complement Progress on Accelerated Drug Approval for Bipolar Depression and Related Disorders: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

August 26, 2024

Via Get News

Topics Regulatory Compliance

Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

August 15, 2024

Via Get News

Topics Regulatory Compliance Retirement

NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q2 2024 ↗

August 14, 2024

NRXP stock results show that NRX Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Alignment with FDA on Pediatric Study Plan and Accelerated Approval to Treat Bipolar Depression and Akathisia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

July 30, 2024

Via Get News

Accelerated Approval to Treat Bipolar Depression and Akathisia Could Yield Over $150 in Revenue Per Share; Planned HOPE Subsidiary Spinoff to Continue: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

July 29, 2024

Via Get News

Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP

August 15, 2024

HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to...

Via PRLog

Topics Regulatory Compliance

NRx Pharmaceuticals Highlights Breakthrough Oral Antidepressant’s Efficacy in Reducing Suicidality in Bipolar Depression at ASCP June 2024 Meeting: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

June 10, 2024

Via Get News

First Oral Antidepressant Clinically Demonstrated to Reduce Suicidality in Bipolar Depression with Data Supporting Accelerated Approval Process: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

May 28, 2024

Via Get News

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 16, 2024

Via Benzinga

NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024 ↗

May 14, 2024

NRXP stock results show that NRX Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update

May 08, 2024

Via ACCESSWIRE

Final Clinical Trial Results Show Superior Safety and Efficacy for NRX-101; Plans to Seek Accelerated Approval for Bipolar Depression and Schizophrenia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

May 06, 2024

Via Get News

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 06, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 01, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 30, 2024

Via Benzinga

Gold Down Over 2%; 3M Profit Beats Expectations ↗

April 30, 2024

Via Benzinga

Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

April 30, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 30, 2024

Via Benzinga

Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study ↗

April 30, 2024

NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression.

Via Benzinga

InvestorNewsBreaks – NRx Pharmaceuticals Inc. Releases Pricing of Public Offering, Expected to Result in Estimated $2M

April 22, 2024

Via Investor Brand Network

Nasdaq Down 0.5%; Lithium Americas Shares Slide ↗

April 18, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 18, 2024

Via Benzinga

Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher ↗

April 18, 2024

Via Benzinga

Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 18, 2024

Via Benzinga

Why Is Bio-Path (BPTH) Stock Up 89% Today? ↗

April 18, 2024

Bio-Path stock is up with heavy trading of BPTH shares today alongside positive news from its ongoing clinical trial of BP1002.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.